Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 29 May 2023
Subanesthetic intravenous ketamine was effective and not inferior to, according to a recent study led by researchers from Mass General Brigham.
Read Full NewsEmerging ADC-Based Strategies in mNSCLC: Interpreting Clinical Evidence and Implications for Practice
Bridging the Gap to CAR T-Cell Therapy for Relapsed/Refractory Multiple Myeloma: An Expert TheraTalk
As we embrace the power of collective knowledge, we must remember that numbers are just numbers
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
"This specific formulation of daunorubicin and cytarabine is not the right choice," experts said
Improvements primarily driven by reduction in incidence of relapse
1.
ASCO: GLP-1 receptor agonists may reduce risk for obesity-related cancer, all-cause death
2.
Preoperative MRI is useful for identifying additional disease in breast cancer patients with nodes positive.
3.
AI catches one-third of interval breast cancers missed at screening
4.
Pivotal Studies in Double-Expressor DLBCL Yield Divergent Results
5.
Chemicals in Sewage Sludge Fertilizer Pose Cancer Risk, EPA Says
1.
Lymphomatoid Papulosis: What You Need to Know
2.
Exploring the Potential of Cytologic Atypia in Cancer Diagnosis
3.
The Rise of Immunotherapy: New Advances in Cancer Treatment
4.
Exploring the Mysteries of Myxoma: A New Frontier in Medical Research
5.
Patient Management Following Organ-Preserving Cancer Interventions
1.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
2.
International Cancer Conference
3.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
4.
Asian Symposium on Advancement in Hematology and Oncology
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Efficient Management of First line ALK-rearranged NSCLC - Part IV
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
3.
Virtual Case Study on Deep Vein Thrombosis (DVT) - An Initiative by Hidoc Dr.
4.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
5.
Influence of CDK4/6 Inhibitors in Extending Progression-Free Survival (PFS) and Overall Survival in HR+/HER2- mBC Patients
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge